Zacks Investment Research upgraded shares of American Renal Associates Holdings, Inc (NYSE:ARA) from a hold rating to a buy rating in a research report sent to investors on Thursday. Zacks Investment Research currently has $13.00 target price on the stock.

According to Zacks, “American Renal Associates Holdings, Inc. is a provider of dialysis services primarily in the United States. It also offers outpatient and inpatient dialysis treatments for patients suffering from chronic kidney failure. American Renal Associates Holdings, Inc. is based in Beverly, Massachusetts. “

Separately, SunTrust Banks, Inc. set a $18.00 target price on shares of American Renal Associates Holdings and gave the stock a buy rating in a report on Sunday, October 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $18.00.

Shares of American Renal Associates Holdings (ARA) traded up $0.41 during trading hours on Thursday, reaching $13.03. 334,046 shares of the company were exchanged, compared to its average volume of 147,346. The company has a market capitalization of $313.66, a PE ratio of 14.88, a price-to-earnings-growth ratio of 0.88 and a beta of 3.64. American Renal Associates Holdings has a 1 year low of $9.91 and a 1 year high of $24.94. The company has a quick ratio of 1.14, a current ratio of 1.17 and a debt-to-equity ratio of 3.69.

American Renal Associates Holdings (NYSE:ARA) last issued its earnings results on Tuesday, November 14th. The company reported $0.19 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm had revenue of $187.71 million during the quarter, compared to analysts’ expectations of $194.60 million. American Renal Associates Holdings had a negative net margin of 2.15% and a positive return on equity of 15.84%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. research analysts predict that American Renal Associates Holdings will post 0.54 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/17/american-renal-associates-holdings-inc-ara-upgraded-to-buy-by-zacks-investment-research.html.

A number of institutional investors have recently bought and sold shares of ARA. Van Berkom & Associates Inc. boosted its stake in American Renal Associates Holdings by 490.5% in the 3rd quarter. Van Berkom & Associates Inc. now owns 2,191,863 shares of the company’s stock worth $32,812,000 after purchasing an additional 1,820,649 shares during the period. Taylor Cottrill Erickson & Associates Inc. acquired a new position in American Renal Associates Holdings in the 2nd quarter worth approximately $12,137,000. Vanguard Group Inc. boosted its stake in American Renal Associates Holdings by 11.6% in the 1st quarter. Vanguard Group Inc. now owns 928,768 shares of the company’s stock worth $15,678,000 after purchasing an additional 96,196 shares during the period. TimesSquare Capital Management LLC boosted its stake in American Renal Associates Holdings by 6.7% in the 2nd quarter. TimesSquare Capital Management LLC now owns 1,290,200 shares of the company’s stock worth $23,933,000 after purchasing an additional 80,650 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in American Renal Associates Holdings by 2,089.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,250 shares of the company’s stock worth $1,340,000 after purchasing an additional 68,950 shares during the period. 89.98% of the stock is owned by hedge funds and other institutional investors.

About American Renal Associates Holdings

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.